Payment overview · 2025
General Payments
$4,271.17
178 reported records · 29 companies
Healthcare provider profile · identity verified
Derek Letort, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · JACKSON, MS · NPI 1023202272
Verified facts
What the public records show
CMS Open Payments records show Derek Letort, M.D. received $4,271.17 in general payments during 2025 across 178 reported records.
ABBVIE INC. accounted for 12.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fycompa, Gocovri, Ingrezza, Nurtec Odt, Xcopri.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tysabri by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fycompa by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Gocovri by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $513.99 | 12.0% | 27 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $383.79 | 9.0% | 20 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $343.65 | 8.1% | 11 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $322.10 | 7.5% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $264.74 | 6.2% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $250.29 | 5.9% | 10 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$239.11 | 5.6% | 8 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $233.59 | 5.5% | 10 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $224.41 | 5.2% | 8 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $220.50 | 5.2% | 9 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $207.46 | 4.9% | 7 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $185.20 | 4.3% | 7 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $170.74 | 4.0% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $149.00 | 3.5% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $89.15 | 2.1% | 4 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $88.67 | 2.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $63.11 | 1.5% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $51.71 | 1.2% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $35.49 | 0.8% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $28.27 | 0.7% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $26.70 | 0.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.62 | 0.6% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$23.84 | 0.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.67 | 0.6% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $23.37 | 0.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.41 | 0.5% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $21.24 | 0.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.09 | 0.5% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $19.26 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,271.17 | 178 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $351.49 | 19 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $351.49 | 19 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $343.65 | 11 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $277.41 | 12 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $250.29 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $230.07 | 8 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $224.41 | 8 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $220.50 | 9 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $210.80 | 8 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $209.31 | 8 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $207.46 | 7 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $183.67 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $134.55 | 11 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $132.42 | 5 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $124.23 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $112.79 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $102.03 | 4 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $101.17 | 5 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $96.47 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | MDD US Operations, LLC | $96.24 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $89.15 | 4 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $88.67 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $72.08 | 7 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $51.14 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $38.25 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $32.30 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $32.30 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $28.27 | 1 | 2025 |
Source payment records
|
|||||
| NOURIANZ Normalized: nourianz |
Drug | KYOWA KIRIN, INC. | $26.70 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $26.11 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $19.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gocovri gocovri |
2025 | Gocovri | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 704 | 148 |
| Primidone | Primidone | 390 | 91 |
| Gabapentin | Gabapentin | 348 | 90 |
| Donepezil Hcl | Donepezil Hcl | 319 | 80 |
| Levetiracetam | Levetiracetam | 301 | 69 |
| Propranolol Hcl | Propranolol Hcl | 264 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 235 | 54 |
| Pregabalin | Pregabalin | 218 | 51 |
| Baclofen | Baclofen | 216 | 49 |
| Memantine Hcl | Memantine Hcl | 205 | 51 |
| Lacosamide | Lacosamide | 183 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 164 | 45 |
| Topiramate | Topiramate | 161 | 50 |
| Amantadine | Amantadine Hcl | 138 | 27 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 135 | 26 |
| Clonazepam | Clonazepam | 117 | 26 |
| Lamotrigine | Lamotrigine | 112 | 22 |
| Zonisamide | Zonisamide | 110 | 18 |
| Oxcarbazepine | Oxcarbazepine | 92 | 19 |
| Trazodone Hcl | Trazodone Hcl | 88 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 15 |
| Rasagiline Mesylate | Rasagiline Mesylate | 62 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 59 | 16 |
| Nortriptyline Hcl | Nortriptyline Hcl | 56 | 14 |
| Divalproex Sodium | Divalproex Sodium | 53 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 53 | 15 |
| Diazepam | Diazepam | 51 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | suppressed |
| Entacapone | Entacapone | 47 | suppressed |
| Meloxicam | Meloxicam | 46 | 11 |
| Carbamazepine | Carbamazepine | 45 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 43 | 12 |
| Neupro | Rotigotine | 37 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 35 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Gocovri | Amantadine Hcl | 31 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 26 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Prednisone | Prednisone | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 24 | suppressed |
| Rytary | Carbidopa/Levodopa | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 18 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Xcopri | Cenobamate | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Ingrezza | Valbenazine Tosylate | 14 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 14 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 13 | suppressed |
| Exelon | Rivastigmine | 13 | suppressed |
| Fycompa | Perampanel | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Tysabri | Natalizumab | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Tecfidera | Dimethyl Fumarate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,271.17 · 178 records | ABBVIE INC. | AJOVY, AMPYRA, AMVUTTRA, AUSTEDO XR, BOTOX, Briviact, CREXONT, ETERNA, Exablate, FYCOMPA, Gocovri, Hizentra, INBRIJA, INGREZZA, KISUNLA, LEQEMBI, NOURIANZ, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, QULIPTA, Qelbree, REXULTI, SKYCLARYS, Symbravo, UBRELVY, ULTOMIRIS, VALTOCO, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WaveWriter Alpha Prime 16, XCOPRI, Xeomin, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fycompa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amneal Pharmaceuticals LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error